CA2800018C - Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders - Google Patents

Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders Download PDF

Info

Publication number
CA2800018C
CA2800018C CA2800018A CA2800018A CA2800018C CA 2800018 C CA2800018 C CA 2800018C CA 2800018 A CA2800018 A CA 2800018A CA 2800018 A CA2800018 A CA 2800018A CA 2800018 C CA2800018 C CA 2800018C
Authority
CA
Canada
Prior art keywords
mir
polynucleotide
nucleic acid
bone
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2800018A
Other languages
English (en)
French (fr)
Other versions
CA2800018A1 (en
Inventor
Johannes Grillari
Elisabeth Schraml
Klaus Fortschegger
Regina Grillari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet fuer Bodenkultur Wien BOKU
Original Assignee
Universitaet fuer Bodenkultur Wien BOKU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet fuer Bodenkultur Wien BOKU filed Critical Universitaet fuer Bodenkultur Wien BOKU
Publication of CA2800018A1 publication Critical patent/CA2800018A1/en
Application granted granted Critical
Publication of CA2800018C publication Critical patent/CA2800018C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
CA2800018A 2010-05-21 2011-05-23 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders Active CA2800018C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10163604 2010-05-21
EP10163604.1 2010-05-21
PCT/EP2011/058379 WO2011144761A1 (en) 2010-05-21 2011-05-23 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders

Publications (2)

Publication Number Publication Date
CA2800018A1 CA2800018A1 (en) 2011-11-24
CA2800018C true CA2800018C (en) 2021-09-28

Family

ID=44537805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2800018A Active CA2800018C (en) 2010-05-21 2011-05-23 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders

Country Status (7)

Country Link
US (3) US20130108687A1 (https=)
EP (1) EP2571988B1 (https=)
JP (1) JP5894581B2 (https=)
CN (1) CN103210085B (https=)
BR (1) BR112012029656A2 (https=)
CA (1) CA2800018C (https=)
WO (1) WO2011144761A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316342A (zh) * 2013-02-28 2013-09-25 中国人民解放军沈阳军区总医院 MiR-31抑制剂用于抑制血管损伤后再狭窄的用途
GB201309882D0 (en) * 2013-06-03 2013-07-17 Isis Innovation Prevention and treatment of atrial fibrillation
US20160120805A1 (en) * 2013-06-05 2016-05-05 The Trustees Of Columbia University In The City Of New York Exosomes for orofacial diagnostics and therapeutics
CN103627705B (zh) * 2013-10-28 2016-02-24 南京医科大学 与膀胱癌相关的piRNA生物标志物及其应用
BR112016028958A2 (pt) * 2014-06-13 2017-10-31 Univ Wien Bodenkultur método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento
US10517888B2 (en) 2014-12-08 2019-12-31 Thomas Jefferson University Treatment and prevention of thrombosis using an anti-miR
JP6694240B2 (ja) * 2015-01-30 2020-05-13 ロート製薬株式会社 細胞の品質を評価する方法、及び細胞の品質判定キット
CN107176976B (zh) * 2016-03-11 2020-02-14 上海交通大学医学院 微小rna31前体编码多肽在制备免疫调节药物中的应用
CN107151695B (zh) * 2016-12-08 2021-11-09 青岛大学 用于检测急性心肌缺血疾病的piRNA组合及其检测方法和应用
CN110129429A (zh) * 2019-05-22 2019-08-16 昌乐县人民医院 核酸分子在制备诊断骨科疾病的产品中的应用
CN110055256A (zh) * 2019-05-31 2019-07-26 固安博健生物技术有限公司 Loc105376287作为诊断男性骨质疏松症的分子标志物的用途
CN110184270A (zh) * 2019-05-31 2019-08-30 固安博健生物技术有限公司 非编码rna作为男性骨质疏松症的诊断标志物
CN110951869B (zh) * 2020-01-02 2021-06-18 北京市创伤骨科研究所 骨质疏松诊治用生物标志物
CN111118139B (zh) * 2020-01-13 2021-06-18 北京市创伤骨科研究所 一种骨质疏松的分子靶标及其应用
CN111599476B (zh) * 2020-05-15 2023-08-11 中南大学湘雅医院 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物
CN112746101B (zh) * 2020-12-25 2023-02-28 深圳市人民医院 一种骨质疏松诊断标志物及促进骨质疏松骨再生的核酸药物
CN114426950B (zh) * 2022-01-25 2023-08-04 北京大学口腔医学院 一种高成骨成血管的血清外泌体及其制备方法和应用
WO2025184665A1 (en) * 2024-03-01 2025-09-04 Immorta Bio, Inc. Senescence vaccine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EP0943684A3 (en) * 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
CA2507496C (en) * 2002-12-05 2014-11-04 John D. Shaughnessy Molecular determinants of myeloma bone disease and uses thereof
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
AR043507A1 (es) 2003-03-14 2005-08-03 Lundbeck & Co As H Derivados de anilina sustituidos y composiciones farmaceuticas
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP1723162A4 (en) * 2004-02-13 2010-05-05 Univ Rockefeller ANTI-microRNA oligonucleotide molecules
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2007888A2 (en) * 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2051964A4 (en) 2006-07-28 2012-03-07 Univ Connecticut INHIBITORS OF FATTY ACID AMIDHYDROLASE
US7993831B2 (en) * 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
EP2414830A2 (en) 2009-03-31 2012-02-08 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US20130210883A1 (en) 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors

Also Published As

Publication number Publication date
JP5894581B2 (ja) 2016-03-30
CN103210085B (zh) 2018-09-25
EP2571988A1 (en) 2013-03-27
BR112012029656A2 (pt) 2016-12-13
US20150119450A1 (en) 2015-04-30
CA2800018A1 (en) 2011-11-24
WO2011144761A1 (en) 2011-11-24
CN103210085A (zh) 2013-07-17
JP2013534908A (ja) 2013-09-09
US9150855B2 (en) 2015-10-06
EP2571988B1 (en) 2019-11-20
US20140162265A1 (en) 2014-06-12
US9212362B2 (en) 2015-12-15
US20130108687A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
CA2800018C (en) Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
US10435689B2 (en) MicroRNA inhibition for the treatment of inflammation and myeloproliferative disorders
EP2566964B1 (en) Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
US20090220589A1 (en) Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US9322015B2 (en) Methods of using microRNA-26a to promote angiogenesis
WO2008029790A1 (fr) Nouvel acide nucléique
WO2012121178A1 (ja) 腫瘍血管形成阻害剤
US10260067B2 (en) Enhancing dermal wound healing by downregulating microRNA-26a
US10519444B2 (en) Methods of reducing expression of X-inactivation escapee genes and autosomal genes
WO2015038593A1 (en) Targeting microrna-26a/b for the treatment of neurodegenerative disease
WO2011130464A1 (en) Translational regulation of sparc by the micrornas mir29a, b and c
EP3843845B1 (en) Inhibition of protein kinases to treat friedreich ataxia
Chen et al. Inhibition of Smurf2 translation by miR-322/503 protects from ischemia reperfusion injury by modulating EZH2/Akt/GSK3β signaling 2
WO2010004816A1 (ja) 肥満細胞の脱顆粒抑制剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140324

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241125